Lead Sponsor

Institut de Recherches Internationales Servier

Collaborators

Age

22 - 55 years

Sex

ALL

Healthy Volunteers

No

•Aged ≥22 and \<55 years with newly-diagnosed and cytologically confirmed and documented Philadelphia-negative B-cell or T-cell ALL by World Health Organization (WHO) classification (2016).
•Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2.
•No prior therapy for ALL such as chemotherapy and radiation therapy before signing the informed consent except for limited treatment (≤7 days) with corticosteroids or hydroxyurea and a single dose of intrathecal cytarabine.

•Patients with Philadelphia chromosome positive ALL, Burkitt's leukemia, mixed lineage/mixed phenotype acute leukemia, and acute undifferentiated leukemia per WHO classification (2016).
•Patients with Down syndrome.
•Patients with Hepatitis B (positive for HBs antigen), and Hepatitis C (HCV antibody) at inclusion
•Participants known to be HIV-positive.
•Known history of non-gallstone-related pancreatitis.
•Known severe hepatic impairment (bilirubin \>3 x upper limit of normal \[ULN\]; transaminases \>10 times ULN.
•Pre-existing history of hepatic veno-occlusive disease (VOD).
•Age ≥ 55 years.
•BMI \> 35 kg/m2.

Related studies

NCT06735690 · Acute Lymphoblastic Leukemia

NCT06074666 · Acute Lymphoblastic Leukemia, Pediatric

NCT04972942 · T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma

NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

SPARK-ALL: Calaspargase Pegol in Adults With ALL